Should a Second Opinion from Specialist Pathologists Be Obtained for Correct Prostate Cancer Treatment?

Gleason scoring is a measure that provides information about the proliferation and spread rates of prostate cancer cells and assesses how much these cells differ from normal cells. It is calculated through microscopic examination by a pathologist of biopsy samples taken from prostate tissue. This score ranges from 2-10, and cancer is known to be more aggressive as the score increases. The study discussed in this article shows that the Gleason score, which is extremely important in the course and treatment of prostate cancer, can produce different results when assessed by specialist pathologists.
In the study, a pathology center specializing in prostate biopsies reassessed biopsies performed at outside centers and read by general pathologists. Prostate cancer is diagnosed by biopsy, as are all cancer types. Pathologists assess tissue samples obtained by biopsy to diagnose prostate cancer; at the same time, the principal indicator of disease aggressiveness, the Gleason score (GS) is calculated. Physicians then try to determine the appropriate treatment option for patients diagnosed with prostate cancer by considering parameters such as age, disease stage, the patient’s general condition and GS.
In this study, biopsy samples from 100 patients recommended for prostate cancer surgery after diagnosis at an outside center were reassessed before surgery by a pathology team specializing in urological cancers; this was called a “second-opinion pathological examination.” The findings showed that in approximately every 10 patients, 1 had an outside-center GS that differed from the second-opinion GS, mostly because the GS had been calculated lower than its actual value. Another finding was that general pathologists recognized prostate cancer spread into fatty tissue (adipose tissue) less often.
Prostate cancer treatment has undergone substantial changes today. Monitoring early-stage, low-risk patients without surgery or medical treatment is being considered; meanwhile, radiotherapy, chemotherapy, robotic surgery, cryoablation, hifu and many other treatment methods have emerged. Appropriate patient selection for these treatments and their correct administration are extremely important for the patient. One of the most fundamental requirements for treating prostate cancer correctly is reliable and accurate pathological assessment. The Gleason score, indicating tumor aggressiveness, is one of the most important guides for us physicians. Tumor extent, the patient’s general condition, accompanying diseases, life expectancy and PSA level are also extremely valuable. However, an incorrect Gleason score will lead the physician toward very inappropriate treatment approaches from the time of diagnosis.
The study we have described shows how valuable a second opinion is in prostate cancer treatment. As demonstrated in the study, the Gleason score can change considerably when assessed by pathologists familiar with urological cancers. If prostate cancer treatment is carried out by multidisciplinary teams that include specialist pathologists, much greater contributions can be made to patients’ lives.
Sources
The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.
Int J Clin Exp Pathol. 2011 Jun 20;4(5):468-75. Epub 2011 Jun 12.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.